Trials / Sponsors / Silverback Therapeutics
Silverback Therapeutics
Industry · 3 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Withdrawn | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Urothelial Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2022-03-01 |
| Terminated | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Can HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer | Phase 1 / Phase 2 | 2022-02-08 |
| Unknown | A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Sol HER2 Positive Solid Tumors | Phase 1 | 2020-07-27 |